OPEN ACCESS

Saudi Journal of Medical and Pharmaceutical Sciences
Abbreviated Key Title: Saudi J Med Pharm Sci
ISSN 2413-4929 (Print) | ISSN 2413-4910 (Online)
Scholars Middle East Publishers, Dubai, United Arab Emirates
Journal homepage: https://saudijournals.com

Review Article **Public Health**

A Multidisciplinary Framework for the Prevention of Contrast-Induced Nephropathy: Synergies in Different Specialties

Tariq Saleh Shahwan Alzahrani[1*], Sharaf Mubarak Ahmed Alzahrani[1], Sultan Saad Mannaa Alamri[2], Ahmed Abdulrhman Alasmari[3], Abdullah Saeed Shukri Alshehri[3], Sulaiman Rames Alshehri[4], Turki Ahmed Alzhrani[4], Adel Saeed Asseri[5], Mastour Awwadh Alharthi[6], Abdulaziz Ali Al amri[6], Ibrahim Mohammed Ghajri[7], Amer Ramzi Albarqi[8], Abdulkarim Antar Q Al Otaibi[9], Modhi Khalid AlHariqi[10]

[1]Public Health Specialist, Preventive Medicine, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia
[2]Anesthesia Technologist, Alhada Armed Forces Hospital, Taif, Saudi Arabia
[3]Pharmacy Technician, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia
[4]X-Ray Technician, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia
[5]Pharmacist, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia
[6]Pharmacy Technician, Prince Mansour Military Hospital, Taif, Saudi Arabia
[7]Pharmacy Technician, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia
[8]Public Health, King Salman Armed Forces Hospital, Tabuk, Saudi Arabia
[9]Anesthesia Technologist, King Fahad Military Medical Complex, Dhahran, Saudi Arabia
[10]Respiratory Therapist, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia

DOI: https://doi.org/10.36348/sjmps.2024.v10i12.022 | **Received:** 17.11.2024 | **Accepted:** 23.12.2024 | **Published:** 30.12.2024

***Corresponding author:** Tariq Saleh Shahwan Alzahrani
Public Health Specialist, Preventive Medicine, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia

Abstract

The administration of iodinated contrast media (ICM) is indispensable for modern diagnostic and interventional procedures. However, the subsequent development of acute kidney injury (AKI) represents a significant clinical challenge, associated with increased morbidity, mortality, and healthcare expenditure. Historically termed contrast-induced nephropathy (CIN), the understanding of this condition has evolved, leading to the more precise term contrast-associated AKI (CA-AKI) to reflect a temporal association rather than assumed causality. The pathophysiology is multifactorial, involving direct tubular cytotoxicity, renal vasoconstriction leading to medullary hypoxia, and oxidative stress. While the risk is low in the general population, it is markedly elevated in patients with pre-existing chronic kidney disease (CKD), diabetes mellitus, heart failure, and in the context of intra-arterial procedures with high contrast volumes. The prevention of CA-AKI has traditionally been managed in departmental silos, an approach that is often fragmented and unreliable. This review proposes a comprehensive, multidisciplinary framework that integrates the expertise of four key pillars: Radiology, Pharmacy, Anesthesia, and Public Health. Effective prevention begins with a shared foundation of robust risk stratification, leveraging quantitative scoring systems and automated electronic health record (EHR) alerts. The Pharmacy pillar focuses on evidence-based pharmacological and medication management, including standardized hydration protocols, controversial adjunctive therapies like N-acetylcysteine and statins, and a critical "nephrotoxic hold" on high-risk medications. The Radiology pillar centers on procedural optimization through the selection of appropriate contrast agents, strict adherence to the principle of dose minimization guided by dose-to-eGFR ratios, and the use of advanced technologies like automated injectors and ultra-low contrast techniques. The Anesthesia pillar provides intraprocedural hemodynamic stewardship for high-risk patients, maintaining renal perfusion through goal-directed fluid therapy and judicious use of vasopressors. Finally, the Public Health pillar provides the system-level architecture for success, designing and implementing hospital-wide "prevention bundles," fostering interdepartmental communication, promoting patient education, and driving continuous quality improvement through audit and feedback. By synergizing these distinct but complementary roles, healthcare systems can transition from a reactive to a proactive and reliable model of care, significantly reducing the clinical and economic burden of CA-AKI.

Keywords: Multidisciplinary Framework, Contrast-Induced, Nephropathy.

1. INTRODUCTION

1.1. Defining the Problem: Contrast-Induced Nephropathy (CIN) vs. Contrast-Associated Acute Kidney Injury (CA-AKI)

For decades, any acute decline in renal function following the administration of iodinated contrast media (ICM) was often summarily labeled as contrast-induced nephropathy (CIN). The classic definition of CIN involves a rise in serum creatinine (SCr) of at least 25% or an absolute increase of 0.5 mg/dL from baseline, typically occurring within 48 to 72 hours of contrast exposure. This terminology, however, inherently implies a direct and singular causal relationship between the contrast agent and the ensuing acute kidney injury (AKI) [1,2].

Increasingly, this assumption has been challenged by a growing body of evidence. Many of the foundational studies that established the concept of CIN were observational and lacked rigorous control groups, often failing to exclude other common causes of AKI in hospitalized patients, such as sepsis, hemodynamic instability, hypovolemia, or concurrent exposure to other nephrotoxic medications. This methodological limitation likely led to a significant overestimation of the true risk directly attributable to ICM, particularly following intravenous (IV) administration for computed tomography (CT) [3].

This recognition has prompted a critical terminological and conceptual shift. Consensus statements from leading bodies, including the American College of Radiology (ACR) and the National Kidney Foundation, now advocate for the use of the term contrast-associated acute kidney injury (CA-AKI) or post-contrast AKI (PC-AKI). These terms more accurately describe a temporal correlation—an episode of AKI occurring within 48 hours of ICM administration—without prematurely assigning causation. The term contrast-induced AKI (CI-AKI) is now more appropriately reserved for the specific subset of CA-AKI in which a direct causal link can be reasonably established after a thorough exclusion of all other potential etiologies.[4]

This is not a purely academic distinction; it has profound clinical implications. The historical fear of CIN fostered a culture of "renalism" or "contrast-phobia," where medically necessary diagnostic studies were often delayed or withheld from patients with even mild renal dysfunction, potentially leading to diagnostic delays and adverse outcomes. Large-scale, propensity-matched studies have since demonstrated that for patients with stable, mild-to-moderate chronic kidney disease (CKD) receiving IV contrast, the incidence of AKI is often no different from that of matched controls who did not receive contrast. The risk of true CI-AKI, however, remains a significant concern in specific high-risk scenarios: patients with severe pre-existing renal impairment (e.g., an estimated glomerular filtration rate <30 mL/min/1.73 m²), and those undergoing intra-arterial (IA) procedures like coronary angiography, where the kidneys are exposed to a higher concentration of the contrast agent. The shift to CA-AKI forces a more thoughtful clinical approach, compelling a differential diagnosis for post-procedure AKI rather than a reflexive attribution to contrast, thereby enabling more rational and patient-centered decision-making.[5]

1.2. Pathophysiology: A brief overview

The pathophysiology of true CI-AKI is a complex interplay of three primary mechanisms that create a vicious cycle of renal injury.[6]

First, ICM induces significant renal hemodynamic alterations. Following a brief, transient period of vasodilation, a more prolonged and intense phase of renal vasoconstriction occurs, particularly affecting the vasa recta at the corticomedullary junction. This is driven by an imbalance in vasoactive mediators, with a reduction in vasodilators like nitric oxide and prostaglandins and an increase in vasoconstrictors such as endothelin and adenosine. The renal medulla, which operates at a state of borderline hypoxia under normal physiological conditions due to its high metabolic demands, becomes profoundly ischemic, leading to cellular injury and dysfunction.[7]

Second, ICM exerts direct cytotoxic effects on the renal tubular epithelial cells. This is characterized by cellular vacuolization, disruption of the cellular cytoskeleton, loss of cell polarity, and ultimately, apoptosis and necrosis. The damaged and necrotic cells slough off into the tubular lumen, forming casts that can lead to tubular obstruction. This obstruction increases intratubular pressure, which opposes glomerular filtration and further compromises renal function.[8]

Third, these processes of ischemia-reperfusion and direct cytotoxicity culminate in a surge of oxidative stress. The generation of reactive oxygen species (ROS) overwhelms the kidney's endogenous antioxidant capacity, leading to widespread damage to cellular lipids, proteins, and DNA. This oxidative burst further exacerbates renal vasoconstriction, inflammation, and endothelial dysfunction, perpetuating the cycle of injury.[9]

1.3. The Public Health Burden: Incidence, prevalence, and impact on morbidity, mortality, and healthcare costs

The reported incidence of CA-AKI varies dramatically across the literature, with figures ranging from less than 2% in the general population to over 50% in select, high-risk patient cohorts. This wide variation is attributable to differences in the definition of AKI used, the prevalence of underlying risk factors in the study population, the type of procedure (IV vs. IA), and the volume of contrast administered. Despite this variability, CA-AKI is consistently recognized as the third most

common cause of hospital-acquired AKI, responsible for approximately 10–15% of all cases.[10]

The development of CA-AKI is far from a benign, transient laboratory abnormality. It is a potent predictor of severe adverse outcomes. Patients who develop CA-AKI experience significantly longer hospital stays, are at higher risk for progression to chronic kidney disease, and have an increased likelihood of requiring temporary or permanent renal replacement therapy. Most alarmingly, CA-AKI is a strong independent predictor of both short- and long-term mortality. In patients undergoing percutaneous coronary intervention (PCI), the development of CA-AKI is associated with a two- to five-fold increase in the risk of death compared to patients without this complication.[11]

This substantial clinical burden translates directly into a significant economic impact. The care of patients with CA-AKI is resource-intensive. A 2022 analysis of a large Medicare database found that a PCI admission complicated by CIN was associated with an average incremental cost of $5,186 compared to an uncomplicated admission. The financial burden extended beyond the index hospitalization, with the cumulative cost difference at one year reaching $10,320 per patient. These excess costs are driven by longer lengths of stay—an average of three additional hospital days in the same study—and the need for more intensive monitoring and treatment, including nephrology consultations and, in severe cases, dialysis.[12]

1.4. The Imperative for Collaboration: Thesis statement on why a siloed approach fails and a multidisciplinary "prevention bundle" is essential

Given the complex, multifactorial pathophysiology of CA-AKI, the diverse patient and procedural risk factors, and the profound clinical and economic consequences, its prevention cannot be the domain of a single clinical department. A siloed approach, in which radiology, pharmacy, anesthesia, or the primary clinical service acts in isolation, is inherently prone to failure due to fragmented communication, inconsistent application of evidence, and missed opportunities for intervention. Effective prevention demands a coordinated, multidisciplinary framework. This review will argue that the most effective strategy is the implementation of a standardized, system-wide "prevention bundle" that synergizes the unique expertise and responsibilities of radiology, pharmacy, anesthesia, and public health. Such a framework ensures reliable identification of at-risk patients and consistent execution of evidence-based interventions across the entire peri-procedural continuum, from the initial imaging order to post-procedure follow-up.[13]

1.5. Aim and Scope

The primary aim of this review is to synthesize the current evidence for CA-AKI prevention and present a comprehensive, multidisciplinary framework for its implementation. The scope of this article will be to: 1) review the evidence for risk stratification and prevention strategies; 2) delineate the specific roles and responsibilities of the four key pillars—Radiology, Pharmacy, Anesthesia, and Public Health—within this collaborative model; 3) propose the components of an integrated, system-level "CA-AKI Prevention Bundle"; and 4) discuss common barriers to implementation and highlight future directions in the field.[14]

2. Risk Stratification: A Shared Foundation

Effective prevention of CA-AKI begins with a robust and reliable system for identifying patients at risk. This process of risk stratification is not the responsibility of a single clinician but a shared foundation upon which the entire multidisciplinary framework is built. It requires a systematic approach to evaluating both patient- and procedure-related factors.[15]

2.1. Identifying the High-Risk Patient

The risk factors for CA-AKI can be broadly categorized into two groups: those inherent to the patient and those related to the contrast procedure itself.[16]

Patient-Related Factors: The single most powerful and consistently identified predictor of CA-AKI is pre-existing chronic kidney disease (CKD). The risk is directly proportional to the severity of renal impairment; as eGFR declines, the incidence of CA-AKI rises precipitously. The risk is approximately 5% for an eGFR \ge60, 15% for an eGFR of 30–44, and can exceed 30% for patients with an eGFR <30 mL/min/1.73 m². Other major patient-related risk factors that compound the risk of CKD include diabetes mellitus, particularly when coexisting with nephropathy; advanced age (often defined as >75 years); congestive heart failure (CHF), especially with New York Heart Association (NYHA) class III-IV symptoms; and any condition that leads to effective volume depletion or renal hypoperfusion, such as dehydration, sepsis, or systemic hypotension.[17]

Procedure-Related Factors: The context of the contrast administration is critically important. Intra-arterial (IA) administration, as seen in coronary or peripheral angiography, carries a substantially higher risk than intravenous (IV) administration for CT scans. This is due to the direct delivery of a high-concentration bolus of contrast to the renal arteries, bypassing first-pass dilution in the cardiopulmonary circulation. The total volume of contrast administered is a key modifiable risk factor; the risk of CA-AKI increases in a dose-dependent manner. Finally, repeated exposures to contrast media within a short period, typically defined as 48–72 hours, can have a cumulative effect and significantly elevate the risk of AKI.[18]

2.2. Quantitative Risk Assessment: Utility and limitations of predictive models

To move beyond a simple checklist of risk factors, several quantitative scoring systems have been developed to provide a more objective estimate of an individual patient's risk. The most widely known and validated of these is the Mehran score, which was developed and validated in a large cohort of patients undergoing PCI.[19]

The Mehran score is an integer-based system that incorporates eight readily available clinical and procedural variables (Table 1). The sum of the points stratifies patients into four risk categories, with predicted rates of CIN ranging from 7.5% in the low-risk group to 57.3% in the very high-risk group, and a risk of requiring dialysis ranging from 0.04% to 12.6%.[20]

While the Mehran score is a valuable tool for research and for quantifying risk, it possesses a significant operational limitation that curtails its utility as a purely *pre-procedural* screening instrument. One of its eight components is the total volume of contrast administered—a variable that is, by definition, unknown until the procedure is completed. The primary clinical purpose of a risk score is to identify patients who would benefit from prophylactic measures *before* the contrast is given. Because the final Mehran score can only be calculated retrospectively, its role in proactive clinical decision-making is limited. Clinicians can only estimate a pre-procedural score by anticipating the contrast volume. This paradox highlights a crucial distinction between a model's statistical accuracy and its practical applicability at the point of care. This has led to the development of modified, pre-procedural scores that omit contrast volume, which, despite a potential small loss in predictive power, offer greater utility for triggering timely preventive interventions.[21]

2.3. The Radiology Role in Screening

The radiology department serves as the primary gatekeeper for contrast administration and plays a pivotal role in the initial screening process. This role begins with the principle of justification, where the radiologist or ordering clinician must carefully weigh the diagnostic benefit of a contrast-enhanced study against the potential risk of CA-AKI, particularly in patients with known risk factors. Alternative non-contrast imaging modalities should always be considered.[22]

The most critical and non-negotiable step in screening is the assessment of baseline renal function. Every patient scheduled to receive intravascular iodinated contrast must have a recent SCr and a calculated eGFR available for review. Institutional policies must clearly define what constitutes a "recent" value, which may vary based on clinical stability (e.g., within 30 days for a stable outpatient versus within 24 hours for an acutely ill inpatient). Radiology departments must establish and enforce clear, evidence-based eGFR thresholds that trigger a "high-risk" pathway. A common threshold is an eGFR <30 mL/min/1.73 m², or an eGFR <45 mL/min/1.73 m² in the presence of other risk factors like diabetes.[23]

2.4. The Public Health Role in Screening: Implementing hospital-wide, automated eGFR flagging and "pop-up" alerts in electronic health records (EHRs)

Relying solely on manual chart review to identify high-risk patients is an unreliable process prone to human error and oversight. A public health approach leverages health information technology to create a robust, automated safety net. This is achieved by embedding clinical decision support tools within the Electronic Health Record (EHR).[24]

When a provider places an order for a contrast-enhanced imaging study, the EHR can be programmed to automatically query the patient's most recent laboratory data. If the latest eGFR falls below a pre-defined institutional threshold (e.g., <45 mL/min/1.73 m²), a "pop-up" alert or Best Practice Advisory (BPA) is triggered. This alert serves as a "forcing function," interrupting the ordering workflow and requiring the provider to actively acknowledge the patient's elevated risk. Ideally, the alert should link directly to the institutional CA-AKI prevention protocol or order set, facilitating the initiation of appropriate measures like IV hydration.[25]

Case studies from institutions that have implemented such systems demonstrate their effectiveness. These automated alerts have been shown to significantly increase the proportion of high-risk patients receiving prophylactic therapies and have been associated with a measurable decrease in the overall incidence of CA-AKI. A key challenge in designing these systems is to avoid "alert fatigue," where an excessive number of low-yield or irrelevant alerts leads clinicians to habitually override them. Therefore, alerts must be carefully designed, targeted, and periodically reviewed by a multidisciplinary governance committee to ensure they remain effective and clinically relevant.[26]

3. The Pharmacy Pillar: Pharmacological and Medication Management

The pharmacy department is a cornerstone of any successful CA-AKI prevention program, providing critical expertise in pharmacological prophylaxis, hydration strategies, and the complex management of a patient's home medications.[27]

3.1. The Cornerstone of Prevention: Periprocedural Hydration

Intravenous volume expansion is the most effective, universally accepted, and evidence-based strategy for preventing CA-AKI. The mechanism is multifactorial: hydration increases intravascular volume, which enhances renal blood flow, promotes a brisk diuresis that dilutes the contrast agent within the renal

tubules and shortens its transit time, suppresses the vasoconstrictive renin-angiotensin-aldosterone system, and inhibits the release of antidiuretic hormone.[28]

A significant debate has centered on the optimal composition of the hydration fluid. The rationale for using isotonic sodium bicarbonate is that by alkalinizing the urine, it may reduce the formation of pH-dependent oxygen free radicals that contribute to tubular injury. Several early, smaller randomized trials and subsequent meta-analyses suggested that sodium bicarbonate was superior to isotonic (0.9%) saline in preventing CIN. However, this initial enthusiasm has been tempered by the results of larger, more rigorously conducted trials and more recent, comprehensive meta-analyses. These larger studies have largely failed to demonstrate a significant benefit of sodium bicarbonate over isotonic saline. A 2017 meta-analysis including 22 studies and over 5,000 patients found no difference in the risk of CIN, need for renal replacement therapy, or mortality between the two hydration strategies. Given its equivalent efficacy, lower cost, and wider availability, isotonic saline remains the standard of care for periprocedural hydration.[29]

Regarding the route of administration, intravenous hydration is the preferred and most reliable method for moderate- to high-risk patients, as it guarantees the delivery of a specified volume over a defined period. For low-risk, stable outpatients, structured oral hydration protocols may be a practical and convenient alternative, although evidence is less robust. Recent trials are actively investigating the non-inferiority of oral hydration in higher-risk populations, a development that could significantly streamline care for outpatients if proven safe and effective.[30]

3.2. Controversies in Pharmacoprophylaxis

Beyond hydration, several pharmacological agents have been investigated for their potential to prevent CA-AKI, with varying degrees of success and considerable controversy. A summary of the evidence for key agents is presented in Table 2.[31]

N-acetylcysteine (NAC): For more than two decades, the role of NAC, a thiol-containing antioxidant and vasodilator, has been a subject of intense debate. An initial landmark trial in 2000 reported a remarkable 90% relative risk reduction in CIN, sparking widespread interest and adoption. However, the subsequent years have seen a deluge of clinical trials and meta-analyses with highly conflicting results. Some studies showed benefit, while many others, including large, well-designed trials, found none. A recent comprehensive umbrella review of existing meta-analyses attempted to reconcile this conflicting evidence. It concluded that while NAC administration may be associated with a statistically significant reduction in the incidence of CA-AKI (as defined by changes in serum creatinine), there is no evidence that it improves hard clinical outcomes such as the need for dialysis or all-cause mortality. Despite its uncertain efficacy, NAC continues to be widely used due to its excellent safety profile, low cost, and ease of administration.[32]

Statins: In contrast to the ambiguity surrounding NAC, the evidence for pre-procedural statin therapy is more compelling. Beyond their primary role in lipid management, statins exert potent pleiotropic effects, including anti-inflammatory, antioxidant, and endothelial-stabilizing actions that directly counteract several of the pathophysiological mechanisms of CI-AKI. Multiple meta-analyses of randomized controlled trials have consistently demonstrated that short-term, high-dose statin therapy (e.g., atorvastatin 80 mg or rosuvastatin 40 mg) initiated before coronary angiography significantly reduces the incidence of CA-AKI. This protective effect appears to be a class effect and is evident even in patients with pre-existing renal insufficiency. Although some of the foundational trials underrepresented patients with severe CKD, the strength and consistency of the data support the routine use of periprocedural statins in at-risk patients.[33]

3.3. Medication Reconciliation and Management: The "Nephrotoxic Hold"

One of the most vital functions of the pharmacy pillar is the proactive management of a patient's concurrent medications. A pharmacist-led comprehensive medication reconciliation is essential for all high-risk patients to identify and temporarily discontinue drugs that could potentiate kidney injury.[34]

Metformin: The concern with metformin is not that it causes CA-AKI, but that its accumulation in the setting of AKI from any cause can precipitate rare but life-threatening metformin-associated lactic acidosis. Therefore, current guidelines from bodies like the FDA recommend a conservative approach. Metformin should be withheld at the time of or prior to the procedure and for 48 hours afterward in all patients with an eGFR <60 mL/min/1.73 m². It should only be restarted after renal function has been re-evaluated and confirmed to be stable. For patients with normal renal function (eGFR \ge60 mL/min/1.73 m²), continuing metformin is now considered safe.[35]

Nonsteroidal Anti-inflammatory Drugs (NSAIDs): NSAIDs inhibit the synthesis of renal prostaglandins, which are crucial for maintaining afferent arteriolar vasodilation and preserving renal blood flow, especially in patients with underlying CKD or volume depletion. The combination of NSAID-induced afferent constriction and contrast-induced vasoconstriction can be particularly injurious. Whenever clinically feasible, NSAIDs should be discontinued 24–48 hours before contrast administration.[36]

Diuretics: By promoting salt and water excretion, diuretics can lead to volume depletion, a primary risk

factor for CA-AKI. The conventional and prudent approach is to hold diuretics on the day of the procedure to avoid exacerbating dehydration and to maximize the benefit of periprocedural IV hydration.[37]

Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors: The role of temporarily holding angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) is highly controversial. These agents cause efferent arteriolar vasodilation, which reduces intraglomerular pressure. While this is protective long-term, it can acutely decrease the GFR during a hemodynamic insult. Some observational data suggest that continuing these drugs may increase the risk of AKI. However, other studies and systematic reviews have found no clear benefit to holding them, and there is concern that abrupt withdrawal, particularly in patients with severe heart failure, could lead to hemodynamic decompensation. The decision to hold or continue RAAS inhibitors must be individualized, weighing the potential risk of AKI against the risk of exacerbating underlying cardiovascular disease.[38]

3.4. Developing Standardized Pharmacy Protocols

To ensure these critical medication management steps are performed reliably, pharmacy departments should spearhead the development of standardized institutional protocols. This can be operationalized through the creation of dedicated "CA-AKI Prevention" order sets within the EHR. These order sets can bundle IV hydration, pre-procedure statin administration, and explicit instructions for holding metformin, NSAIDs, and diuretics. Furthermore, establishing a formal pharmacist-led consultation service for all high-risk patients can significantly enhance safety. In this model, a clinical pharmacist reviews the patient's case, provides tailored medication management recommendations, counsels the patient, and serves as a key communication link between the primary team and the procedural service, ensuring a seamless and safe peri-procedural course.[39]

4. The Radiology Pillar: Optimizing the Imaging Procedure

The radiology department or cardiac catheterization laboratory, as the site of contrast administration, holds direct responsibility for optimizing the procedure to minimize renal risk. This involves careful consideration of the type and, most importantly, the volume of contrast used, as well as leveraging technology and technique to achieve diagnostic goals with maximal safety.[40]

4.1. The Contrast Media Debate: "Which Agent?"

Modern iodinated contrast media are categorized based on their osmolality relative to blood plasma (\approx290 mOsm/kg). High-osmolar contrast media (HOCM), with osmolalities 5–8 times that of plasma, have been largely abandoned due to their established higher rates of nephrotoxicity and adverse events. The current standard of care involves the use of either low-osmolar contrast media (LOCM), which have an osmolality 2–3 times that of plasma, or iso-osmolar contrast media (IOCM), which are isotonic to plasma.[41]

Iodixanol is the only IOCM available for intravascular use. Initial studies, particularly in high-risk patients with diabetes and CKD, suggested that iodixanol was associated with a lower risk of nephropathy compared to various LOCM agents. This led to a period of preferential use in high-risk populations. However, subsequent, larger randomized controlled trials (RCTs) and comprehensive meta-analyses have challenged this initial finding. A major meta-analysis of 25 RCTs published in the *Annals of Internal Medicine* found that while iodixanol was associated with a statistically significant reduction in CIN risk compared to a heterogeneous group of LOCMs, the magnitude of this effect was small and did not meet the pre-specified threshold for clinical importance. Other large-scale propensity-matched observational studies have found no significant difference in the incidence of CA-AKI between LOCM and IOCM, even within high-risk subgroups. The current consensus, particularly for IV contrast administration, is that there is no clinically meaningful difference in the risk of CA-AKI between modern LOCM and IOCM. Consequently, the focus of prevention has rightly shifted from the specific agent chosen to the total volume administered.[42]

4.2. The Volume Principle: "How Much?"

Minimizing the total volume of contrast media is arguably the single most effective intraprocedural strategy for reducing the risk of CA-AKI. The risk of renal injury is clearly dose-dependent. A crucial concept in procedural planning is the ratio of contrast dose to the patient's renal function. Exceeding a certain threshold is associated with a sharp, non-linear increase in the risk of AKI. While various formulas exist, a commonly cited threshold is keeping the ratio of contrast volume (in mL) to the patient's eGFR (in mL/min) below 2.0, or ensuring the total volume does not exceed the maximal acceptable contrast dose (MACD), often calculated as [5 \times \text{body weight (kg)}] / \text{serum creatinine (mg/dL)}].[43]

To operationalize this principle, institutions should establish and audit adherence to these dose-to-eGFR limits. For every high-risk patient, a maximum allowable contrast dose should be calculated *before* the procedure begins. This safety limit should be explicitly stated and acknowledged by the entire procedural team during the pre-procedure "timeout" or team huddle, just like verifying the correct patient and surgical site.[44]

4.3. Technological and Technical Adjuncts

Several technologies and techniques can be employed to adhere to the principle of dose minimization while maintaining diagnostic quality.[45]

Automated Contrast Injectors: Compared to traditional manual injection via a manifold, automated contrast injection systems offer precise control over injection volume and flow rate. Meta-analyses have shown that the use of these systems is associated with a significant reduction in the total contrast volume used per procedure and a corresponding decrease in the incidence of CA-AKI. They also provide an accurate, automated record of the volume administered, which is crucial for quality auditing.[46]

Ultra-low and Zero-Contrast Techniques: For the highest-risk patients, particularly those with severe CKD undergoing PCI, advanced contrast-sparing techniques are becoming the standard of care. These "ultra-low-contrast PCI" (ULCPCI) or "zero-contrast PCI" approaches minimize or eliminate the need for traditional angiography. They rely heavily on adjunctive imaging and physiological tools. Intravascular ultrasound (IVUS) or optical coherence tomography (OCT) provide detailed anatomical information for lesion assessment and stent sizing, while coronary physiology measurements (e.g., fractional flow reserve or instantaneous wave-free ratio) determine the hemodynamic significance of stenoses. The procedure is guided by using a previous diagnostic angiogram as a "roadmap," using coronary calcifications as landmarks, and confirming guide catheter engagement with vigorous saline injections that produce transient ECG changes.[47]

Non-contrast Alternatives: For certain clinical questions in the highest-risk patients, alternative imaging modalities that do not use iodinated contrast should be considered. For peripheral vascular imaging, carbon dioxide (CO_2) can be used as a negative contrast agent. Non-contrast magnetic resonance angiography (MRA) has advanced significantly and can provide excellent vascular imaging without any contrast agent. Contrast-enhanced ultrasound (CEUS) is another option for specific applications. While these alternatives may have limitations in spatial resolution or applicability, their use can be justified when the risk of CA-AKI with conventional angiography is deemed prohibitive. The cost-effectiveness of these modalities must be weighed against the significant cost of treating a potential episode of CA-AKI.[48]

4.4. The Radiologist-Patient Dialogue

In the context of elective procedures for patients identified as high-risk, the proceduralist's role extends to effective risk communication and shared decision-making. This involves a clear discussion with the patient and their family about the specific risks of CA-AKI, the potential benefits of the contrast-enhanced procedure, the preventive measures that will be taken, and any available alternative diagnostic options. Using absolute risk figures derived from prediction models (e.g., "Based on your health profile, your risk of temporary kidney injury from this procedure is about 25%") and simple visual aids can be more effective than vague warnings. This dialogue is a cornerstone of patient-centered care and the informed consent process.[49]

5. The Anesthesia Pillar: Intraprocedural Hemodynamic Stewardship

For many routine diagnostic imaging studies, the involvement of an anesthesiologist is not required. However, for a significant subset of high-risk patients undergoing lengthy, complex, or emergent procedures such as endovascular aneurysm repair (EVAR), transcatheter aortic valve replacement (TAVR), or complex multi-vessel PCI, the anesthesiologist's role is paramount. In these settings, the anesthesiologist functions as the primary steward of the patient's intraprocedural physiology, with a critical responsibility to protect end-organ perfusion, particularly that of the kidneys.[50]

5.1. Anesthesia's Unique Role: Protecting renal perfusion in high-risk, complex, or lengthy procedures

Patients undergoing major endovascular or cardiac interventions are often elderly and burdened with multiple comorbidities, including pre-existing renal dysfunction, heart failure, and diffuse atherosclerosis. The combination of anesthesia, surgical stress, potential blood loss, and a significant contrast load places them at extremely high risk for postoperative AKI. The anesthesiologist is uniquely positioned to mitigate this risk through meticulous, real-time management of hemodynamics and fluid balance, transforming the intraprocedural period from a high-risk event into a window for active renal protection.[51]

5.2. Maintaining Renal Blood Flow

The Danger of Hypotension: Intraprocedural hypotension is a powerful and independent predictor of postoperative AKI. The kidneys possess an autoregulatory mechanism that maintains constant renal blood flow (RBF) across a range of systemic blood pressures. However, below a critical threshold—typically a mean arterial pressure (MAP) of 60–70 mmHg in normotensive individuals—this autoregulation fails, and RBF becomes passively dependent on perfusion pressure. In patients with chronic hypertension, this autoregulatory curve is shifted to the right, meaning a higher MAP is required to maintain adequate RBF. Therefore, a key goal of the anesthesiologist is to prevent and aggressively treat hypotension. While a universal target is not established, maintaining the MAP within 20% of the patient's baseline preoperative value is a widely accepted and prudent strategy.[52]

Choice of Vasopressors and Inotropes: When hypotension persists despite adequate fluid resuscitation, vasopressor therapy is necessary. Historically, there was concern that alpha-adrenergic agonists like

norepinephrine would induce renal vasoconstriction and worsen kidney function. However, extensive research, particularly in the setting of distributive shock, has refuted this notion. In a hypotensive state, the systemic vasodilation is often more profound than any localized renal vasoconstriction. By restoring systemic MAP and thus renal perfusion pressure, agents like norepinephrine can paradoxically improve RBF, glomerular filtration, and urine output. The beneficial effect of restoring systemic pressure outweighs the potential for direct renal vasoconstriction.[53]

5.3. Goal-Directed Fluid Therapy

The traditional approach of administering a fixed, weight-based rate of intravenous fluids during a procedure is a one-size-fits-all strategy that is suboptimal for high-risk patients. Both hypovolemia (which exacerbates ischemic injury) and iatrogenic fluid overload (which can lead to renal venous congestion and worsen AKI) are detrimental.[54]

Goal-directed fluid therapy (GDFT) represents a more sophisticated, individualized approach. GDFT utilizes dynamic parameters derived from an arterial waveform analysis, such as stroke volume variation (SVV) or pulse pressure variation (PPV), to assess a patient's fluid responsiveness. These variables quantify the degree to which the stroke volume changes with respiration, providing a real-time indicator of whether the patient is on the steep, preload-dependent portion of their Frank-Starling curve. The anesthesiologist administers fluid boluses only when these dynamic markers indicate that the patient is likely to respond with an increase in cardiac output. This tailored strategy of giving "the right amount of fluid at the right time" has been shown in multiple studies to be superior to standard fluid therapy, resulting in a lower incidence of postoperative AKI and improved patient outcomes.[55]

5.4. Emerging Concepts: Anesthetic preconditioning and remote ischemic preconditioning (RIPC) as potential protective strategies

Beyond hemodynamic management, emerging strategies aim to precondition the kidneys to better withstand the ischemic insult associated with contrast media and surgical procedures.[56]

Anesthetic Preconditioning: Volatile anesthetic agents such as sevoflurane and isoflurane have been shown in numerous experimental models to induce a state of cellular protection against ischemia-reperfusion injury, a phenomenon known as anesthetic preconditioning. This effect, mediated through complex intracellular signaling pathways involving mitochondria, may confer a protective advantage for the kidneys and other organs compared to total intravenous anesthesia (TIVA) with agents like propofol. While clinical evidence in the specific context of CA-AKI is still developing, the use of volatile anesthetics may be a beneficial consideration in high-risk vascular surgery patients.[57]

Remote Ischemic Preconditioning (RIPC): RIPC is a non-invasive and remarkably simple technique that involves inducing brief, controlled episodes of ischemia and reperfusion in a remote tissue, typically a limb, using a standard blood pressure cuff. This stimulus triggers the release of protective humoral factors into the circulation, which then confer resistance to ischemia-reperfusion injury in distant organs like the heart and kidneys. A prospective, randomized, double-blind controlled trial in patients with CKD undergoing cardiovascular angiography demonstrated that RIPC, performed immediately before the procedure, resulted in a significant reduction in the incidence of CIN compared to a sham procedure (12% vs. 30%). As a low-cost, low-risk intervention, RIPC represents a highly promising adjunctive strategy that warrants further large-scale investigation.[58]

6. The Public Health Pillar: System-Level Implementation and Quality Improvement

While the preceding pillars focus on the specific clinical actions of individual specialties, the public health pillar provides the overarching structure required to ensure these actions are performed reliably, consistently, and effectively for every at-risk patient. This involves moving from individual best practices to a standardized, system-wide program of care.[59]

6.1. From Evidence to Practice: Designing and implementing a hospital-wide "CIN Prevention Bundle"

The concept of "care bundles," pioneered by the Institute for Healthcare Improvement (IHI), has been highly successful in reducing healthcare-associated infections like central line-associated bloodstream infections (CLABSI) and ventilator-associated events (VAE). A bundle is a small, structured set of evidence-based interventions—typically 3 to 5—that, when implemented collectively and reliably, result in better outcomes than when implemented individually.[60]

The same principle can be applied to CA-AKI prevention. A multidisciplinary team should be convened to develop a standardized "CA-AKI Prevention Bundle" tailored to the local institutional context. The strength of the bundle lies in its "all-or-none" approach: success is measured not by performing some of the elements, but by ensuring that every eligible patient receives every element of the bundle, every time. This approach fosters a culture of high reliability. An example of a comprehensive, multidisciplinary bundle is detailed in Table 3.[61]

6.2. The Power of the "Huddle": Creating a formal communication pathway for high-risk cases

Technology and protocols are essential, but they cannot replace direct human communication. For every patient identified as high-risk via the automated EHR alert, a mandatory pre-procedure "huddle" should

be triggered. This can be a brief virtual or in-person meeting involving key members from the primary team, pharmacy, radiology/procedural service, and anesthesia (if involved). The purpose of the huddle is to ensure universal awareness of the patient's risk, confirm that all elements of the pre-procedure bundle have been completed, agree on the intraprocedural plan (e.g., the MACD), and clarify post-procedure responsibilities. This simple, structured communication step closes dangerous gaps and prevents critical tasks from being missed due to flawed assumptions.[62]

6.3. Patient Education and Engagement

An effective public health strategy empowers patients to be active participants in their own safety. This requires the development of clear, concise, and accessible patient education materials. These materials, which can take the form of brochures, websites, or short videos, should be written at an appropriate health literacy level and explain in simple terms what CA-AKI is, why the patient is at risk, and what steps will be taken to protect their kidneys. Most importantly, they should clearly outline the patient's role, such as adhering to oral hydration instructions, understanding which medications to temporarily stop, and knowing the symptoms that warrant a call to their provider post-procedure. This engagement fosters a partnership and enhances adherence to the prevention plan.[63]

6.4. Audit, Feedback, and Quality Improvement (QI)

Implementing a prevention bundle is not a one-time event; it is the beginning of a continuous cycle of quality improvement. A robust QI program is essential for sustaining and enhancing the program's effectiveness.[64]

Audit: The institution must commit to tracking key performance indicators (KPIs). This includes outcome measures, such as the hospital-wide incidence of CA-AKI (stratified by risk and procedure type), and process measures, such as the compliance rate with each individual element of the prevention bundle (e.g., percentage of high-risk patients receiving pre-hydration, percentage of procedures adhering to the MACD).[65]

Feedback: This data must be fed back to the frontline clinicians in a regular, timely, and non-punitive manner. Effective feedback reports often show an individual provider's performance data benchmarked against their anonymized peers, both at the local site and across the health system. This comparative data is a powerful motivator for self-reflection and practice change.[66]

Quality Improvement: When audits reveal gaps in performance (e.g., low compliance with medication holds), a formal QI methodology, such as the Plan-Do-Study-Act (PDSA) cycle, should be used to analyze the root causes of the failure and test targeted interventions to improve the process.

Economic Analysis: A critical component of a mature QI program is demonstrating its value to hospital leadership. By tracking the costs associated with treating CA-AKI (e.g., increased length of stay, dialysis costs) and comparing them to the relatively low costs of the prevention program (e.g., IV fluids, pharmacist time), the QI team can calculate a return on investment. Demonstrating that prevention is not only clinically superior but also cost-effective is crucial for securing the long-term resources and institutional support needed to sustain the program.

7. CONCLUSION

The prevention of contrast-associated acute kidney injury represents a complex but manageable challenge in modern healthcare. The evolution in terminology from CIN to CA-AKI reflects a more nuanced understanding that post-contrast renal dysfunction is often multifactorial, compelling a shift from a focus on the contrast agent itself to a holistic focus on the vulnerable patient. The evidence strongly supports a core set of preventive strategies: robust risk stratification based on eGFR and clinical factors, meticulous periprocedural hydration with isotonic saline, minimization of contrast volume guided by dose-to-eGFR ratios, and judicious management of concurrent nephrotoxic medications.

However, the consistent and reliable delivery of these interventions is the true crux of effective prevention. This review has argued that a fragmented, departmental approach is insufficient. Success can only be achieved through a dynamic, collaborative process that formally integrates the distinct expertise of multiple clinical disciplines. Radiology must champion procedural optimization and justification. Pharmacy must lead evidence-based medication management. Anesthesia must provide dedicated hemodynamic stewardship. And Public Health principles must be applied to create the system-level architecture—through automated alerts, standardized bundles, and continuous quality improvement—that enables and sustains this collaborative work. By breaking down silos and building a synergistic, multidisciplinary framework, healthcare institutions can transform the prevention of CA-AKI from an aspiration into a reliable standard of care, improving patient safety and reducing the significant human and economic costs of this preventable complication.

REFERENCES

1. Contrast-induced nephropathy - Wikipedia, https://en.wikipedia.org/wiki/Contrast-induced_nephropathy
2. Does Contrast cause acute Kidney Injury? - NephJC, http://www.nephjc.com/news/2016/10/31/contrastaki
3. Contrast-Induced Acute Kidney Injury: The Data and the Debate - Consult QD, https://consultqd.clevelandclinic.org/contrast-

induced-acute-kidney-injury-the-data-and-the-debate
4. Full article: Contrast-Induced Acute Kidney Injury: Evidence in Support of Its Existence and a Review of Its Pathogenesis and Management, https://www.tandfonline.com/doi/full/10.2147/IJNRD.S371700
5. Contrast-Induced Nephropathy - StatPearls - NCBI Bookshelf, https://www.ncbi.nlm.nih.gov/books/NBK448066/
6. Biomarkers in Contrast-Induced Nephropathy: Advances in Early Detection, Risk Assessment, and Prevention Strategies - MDPI, https://www.mdpi.com/1422-0067/26/7/2869
7. Contrast-induced acute kidney injury: a review of definition, pathogenesis, risk factors, prevention and treatment - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC11034108/
8. (PDF) Incidence of contrast-induced nephropathy a prospective study - ResearchGate, https://www.researchgate.net/publication/322445434_Incidence_of_contrast-induced_nephropathy_a_prospective_study
9. Epidemiology, Clinical Features and Diagnosis of Contrast Induced Nephropathy: A Brief Review, https://www.iomcworld.com/open-access/epidemiology-clinical-features-and-diagnosis-of-contrast-induced-nephropathy-a-brief-review-2327-5146.1000102.pdf
10. Contrast-induced nephropathy in invasive cardiology - Swiss Medical Weekly, https://smw.ch/index.php/smw/article/view/1507/1899
11. Risk factors for contrast induced nephropathy: A study among Italian patients - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC3860804/
12. Contrast-induced nephropathy after endovascular interventions in peripheral artery disease: Predictive value of the Mehran score, https://e-cvsi.org/pdf.php3?id=423
13. Contrast-associated acute kidney injury - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC7188616/
14. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation - RSNA Journals, https://pubs.rsna.org/doi/full/10.1148/radiol.2019192094
15. Contrast-Induced Nephropathy | Circulation - American Heart Association Journals, https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.115.014672
16. Contrast-Associated Acute Kidney Injury - MDPI, https://www.mdpi.com/2077-0383/11/8/2167
17. Contrast-induced acute kidney injury | Radiology Reference Article | Radiopaedia.org, https://radiopaedia.org/articles/contrast-induced-acute-kidney-injury
18. Intravenous Contrast Material–induced Nephropathy: Causal or Coincident Phenomenon? | Radiology - RSNA Journals, https://pubs.rsna.org/doi/full/10.1148/radiol.12121823
19. Pathophysiology of contrast-induced nephropathy - PubMed, https://pubmed.ncbi.nlm.nih.gov/16949376/
20. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC557983/
21. Pathogenesis of Acute Renal Failure Induced by Iodinated Radiographic Contrast Media, https://austinpublishinggroup.com/nephrology/fulltext/ajnh-v1-id1005.php
22. Effect of IV Injection of Radiographic Contrast Media on Human Renal Blood Flow | AJR, https://ajronline.org/doi/10.2214/AJR.06.1170?doi=10.2214/AJR.06.1170
23. Preventing Contrast-induced Renal Failure: A Guide | ICR Journal, https://www.icrjournal.com/articles/preventing-contrast-induced-renal-failure-guide?language_content_entity=en
24. Prevention of contrast-associated acute kidney injury in an era of increasingly complex interventional procedures - Frontiers, https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1180861/full
25. Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches, https://d-nb.info/1222858436/34
26. The Pathophysiology and the Management of Radiocontrast-Induced Nephropathy - MDPI, https://www.mdpi.com/2075-4418/12/1/180
27. Iodinated contrast media cause direct tubular cell damage, leading to oxidative stress, low nitric oxide, and impairment of tubuloglomerular feedback, https://pmc.ncbi.nlm.nih.gov/articles/PMC4422341/
28. Prevention of Contrast-Induced Nephropathy (CIN) in Interventional Radiology Practice - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC3324211/
29. Iodinated contrast media cause direct tubular cell damage, leading to oxidative stress, low nitric oxide, and impairment of tubuloglomerular feedback - American Physiological Society Journal, https://journals.physiology.org/doi/abs/10.1152/ajprenal.00302.2013
30. A Novel Antioxidant Protects Against Contrast Medium-Induced Acute Kidney Injury in Rats, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.599577/full

31. Predictors of contrast-induced nephropathy in chronic total occlusion percutaneous coronary intervention | EuroIntervention, https://eurointervention.pcronline.com/article/predictors-of-contrast-induced-nephropathy-in-chronic-total-occlusion-percutaneous-coronary-intervention
32. Contrast-Induced Nephropathy in Endovascular Patients: A Retrospective Cohort Study from a Vascular Surgery Clinic in Eastern Europe - MDPI, https://www.mdpi.com/2077-0383/14/4/1172
33. Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial | European Heart Journal | Oxford Academic, https://academic.oup.com/eurheartj/article/45/18/1647/7633084
34. Contrast-Induced Acute Kidney Injury Among Patients With Chronic Kidney Disease Undergoing Imaging Studies: A Meta-Analysis | AJR - American Journal of Roentgenology, https://ajronline.org/doi/10.2214/AJR.19.21309
35. Beneficial effect of statin on preventing contrast-induced acute kidney injury in patients with renal insufficiency: A meta-analysis - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC7478506/
36. The Incidence of Contrast-Induced Nephropathy and the Need of Dialysis in Patients Receiving Angiography: A Systematic Review and Meta-Analysis - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC9091353/
37. Contrast-induced Nephropathy in a High-risk Patient Population | ICR Journal, https://www.icrjournal.com/articles/contrast-induced-nephropathy-high-risk-patient-population?language_content_entity=en
38. Contrast-Induced Nephropathy (CIN) After Invasive Treatment of Acute Coronary Syndromes—Predictors, Short and Long-Term Outcome - MDPI, https://www.mdpi.com/2077-0383/14/11/3725
39. Economic Impact of Contrast-Induced Nephropathy in Percutaneous Coronary Intervention: A Medicare Payer Perspective - ISPOR, https://www.ispor.org/docs/default-source/intl2022/ispor-2022---cin-in-pci-lt-cost-posterfinal-pdf.pdf?sfvrsn=acfd8a20_0
40. Contrast-induced nephropathy following angiography and cardiac interventions - Heart, https://heart.bmj.com/content/102/8/638
41. Economic burden of contrast-induced nephropathy (CIN): Implications for prevention strategies | Request PDF - ResearchGate, https://www.researchgate.net/publication/251648835_Economic_burden_of_contrast-induced_nephropathy_CIN_Implications_for_prevention_strategies
42. Contrast Induced Nephropathy | Hospital Handbook, https://hospitalhandbook.ucsf.edu/05-contrast-induced-nephropathy/05-contrast-induced-nephropathy
43. Predicting contrast induced nephropathy in patients undergoing percutaneous coronary intervention - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC6688022/
44. Performance of a Pre-Procedural Mehran Score to Predict Acute Kidney Injury After Percutaneous Coronary Intervention - Biomedical Journal of Scientific & Technical Research, https://biomedres.us/pdfs/BJSTR.MS.ID.004391.pdf
45. Contrast-Induced Nephropathy | AJR - American Journal of Roentgenology, https://ajronline.org/doi/10.2214/ajr.183.6.01831673
46. Radiology Patient Safety and Communication - StatPearls - NCBI Bookshelf, https://www.ncbi.nlm.nih.gov/books/NBK567713/
47. Proportion of Contrast-Induced Nephropathy (CIN) Prevention Therapy Implementation, https://www.snubh.org/outcomesbookEN/filedownload.do?mode=55
48. Electronic alert outpatient protocol improves the quality of care for the risk of postcontrast acute kidney injury following computed tomography - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC10565459/
49. Implementation of an Electronic Health Records–Based Safe Contrast Limit for Preventing Contrast-Associated Acute Kidney Injury After Percutaneous Coronary Intervention | Circulation: Cardiovascular Quality and Outcomes, https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.122.009235
50. Implementation of an Electronic Health Records-Based Safe Contrast Limit for Preventing Contrast-Associated Acute Kidney Injury After Percutaneous Coronary Intervention, https://pmc.ncbi.nlm.nih.gov/articles/PMC9858238/
51. Prevention of Contrast-Induced Renal Failure for the Interventional Cardiologist | Circulation, https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.116.004122
52. Strategies to Reduce the Risk of Contrast-Induced Nephropathy - ResearchGate, https://www.researchgate.net/publication/6841287_Strategies_to_Reduce_the_Risk_of_Contrast-Induced_Nephropathy
53. What are the methods for preventing contrast-induced nephropathy (CIN) in patients with impaired renal function? - Dr.Oracle, https://droracle.ai/articles/31105/what-are-the-methods-for-preventing-contrast-induced-nephropathy-cin-in-patients-with-impaired-renal-function

54. The Efficacy of Hydration with Normal Saline Versus Hydration with Sodium Bicarbonate in the Prevention of Contrast-induced Nephropathy, https://applications.emro.who.int/imemrf/Heart_Views/Heart_Views_2014_15_2_33_36.pdf
55. Sodium bicarbonate versus isotonic saline solution to prevent contrast-induced nephropathy: a systematic review and meta-analysis - PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC4640430/
56. Sodium Bicarbonate Versus Saline for the Prevention of Contrast-Induced Nephropathy in Patients With Renal Dysfunction Undergoing Coronary Angiography or Intervention | JACC, https://www.jacc.org/doi/10.1016/j.jacc.2008.05.026
57. Sodium bicarbonate versus isotonic saline solution to prevent contrast-induced nephropathy: A systematic review and meta-analysis - ResearchGate, https://www.researchgate.net/publication/283031947_Sodium_bicarbonate_versus_isotonic_saline_solution_to_prevent_contrast-induced_nephropathy_A_systematic_review_and_meta-analysis
58. Fluid administration strategies for the prevention of contrast-associated acute kidney injury | Request PDF - ResearchGate, https://www.researchgate.net/publication/362094795_Fluid_administration_strategies_for_the_prevention_of_contrast-associated_acute_kidney_injury
59. Preventive Strategies for Contrast Induced Acute Kidney Injury: And The Winner is… - PMC - PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC5508599/
60. Guideline Safe Use of Contrast Media Part 1, https://radiologen.nl/system/files/bestanden/documenten/richtlijn_veilig_gebruik_van_contrastmiddelen_deel_1_1nov2017.pdf
61. Study Details | NCT05283512 | Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT05283512?term=AREA%5BBasicSearch%5D(ACT%20%20contrast%20nephropathy)&rank=3
62. Intravenous versus oral hydration to reduce the risk of postcontrast acute kidney injury after intravenous contrast-enhanced CT in patients with severe chronic kidney disease (ENRICH): a study protocol for a single-centre, parallel-group, open-labelled non-inferiority randomised controlled trial in Denmark - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC10503331/
63. Effectiveness of Oral Hydration in Preventing Contrast-Induced Nephropathy in Individuals Undergoing Elective Coronary Intervention - ABC Cardiol, https://abccardiol.org/wp-content/uploads/articles_xml/0066-782X-abc-120-02-e20220529/0066-782X-abc-120-02-e20220529-en.x47225.pdf
64. Association of N-acetylcysteine use with contrast-induced nephropathy: an umbrella review of meta-analyses of randomized clinical trials - Frontiers, https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1235023/full
65. Intravenous N-Acetylcysteine for Prevention of Contrast-Induced Nephropathy: A Meta-Analysis of Randomized, Controlled Trials | PLOS One - Research journals, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0055124
66. Effectiveness of N-Acetylcysteine for the Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, https://www.ahajournals.org/doi/10.1161/JAHA.116.003968